Skip to main content

Khaitan & Co  and Cyril Amarchand Mangaldas are advising Indian drugmaker Gland Pharma on its planned $780 million IPO, with Herbert Smith Freehills and S&R Associates acting for the bookrunners and lead managers.

The Hyderabad-headquartered Gland Pharma, a subsidiary of China’s Fosun Pharmaceutical, is a major supplier of API heparin to hospitals in India. Its IPO will make it the first Indian company with a Chinese parent to list its equity shares on an Indian stock exchange.

The bookrunning lead managers are Kotak Mahindra Capital, Citigroup Global Markets India, Haitong Securities India and Nomura India.

The Khaitan team is being led by partners Abhimanyu Bhattacharya, Aditya Cheriyan, Niren Patel and Vivek Sriram.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

N&A, S&C, TMI advise as Japan's Nidec makes $1.6 bln bid for Makino Milling

by Asian Legal Business《亚洲法律杂志》 |

TMI Associates, Freshfields and Davis Polk & Wardwell have represented Japanese manufacturing giant Nidec on its 257-billion-yen ($1.6 billion) bid for Makino Milling Machine, which turned to Nishimura & Asahi and Sullivan & Cromwell for advice.

Deals

N&A, MHM, Skadden, STB guide JX Advanced Metal’s $3 bln Japan IPO

by Nimitt Dixit |

Nishimura & Asahi and Skadden Arps Slate Meagher & Flom are advising JX Advanced Metals on its upcoming 460-billion-yen ($3 billion) initial public offering, the largest listing in Japan since SoftBank Corp’s $23.5 billion IPO in 2018.

Deals

Trilegal, Touchstone, CAM act on Carlyle’s $400 mln entry into India auto-components space

by Nimitt Dixit |

Trilegal has advised global private equity firm Carlyle on its acquisition of majority stakes in Highway Industries (HIL) and Roop Automotives for $400 million, marking its entry into India's auto components sector through a new manufacturing platform.